Correlation and risk assessment of serum 25（OH）D level and multiple thyroid function indicators in patients with thyroid cancer before operation

doi:10.3969/j.issn.1673-8640.2020.09.007

Abstract

Abstract:

Objective To investigate the changes of serum 25-hydroxyvitamin D [25（OH）D] levels in patients with thyroid cancer and the correlation with serum thyroid function indicators and the risk of thyroid cancer. Methods A total of 56 patients with thyroid cancer（thyroid cancer group） and 69 patients with benign thyroid nodules（benign nodule group） were enrolled. Serum 25（OH）D,free triiodothyronine（FT₃） and free thyroxine（FT₄）,thyroid-stimulating hormone（TSH）,thyroglobulin（Tg）,thyroid peroxidase antibody（TPOAb） and thyroglobulin antibody（TgAb） levels were determined. According to the level of 25（OH）D,all the subjects were classified into 3 groups,including vitamin D deficiency（≤20 ng/mL）,vitamin D insufficiency（>20-≤30 ng/mL）and vitamin D sufficiency（>30 ng/mL） groups. Spearman correlation analysis was used to evaluate the correlation among various indicators. Odds ratio （OR） and 95% confidence interval （CI） were used to evaluate the risk of thyroid cancer. Results Serum level of 25（OH）D in thyroid cancer group was lower than that in benign nodule group（P<0.01）,and serum TSH level was higher（P<0.05）. There was no statistical significance in the other indicators between the 2 groups（P>0.05）. In thyroid cancer group,25（OH）D was negatively correlated with TSH and TPOAb（r=-0.750 and -0.872,respectively,P<0.01）,and it had no correlation with FT₃,FT₄,Tg and TgAb levels（r=0.104,0.03,-0.134 and -0.149,respectively,P>0.05）. The risk of thyroid cancer was increased when 25（OH）D≤20 ng/mL （OR=7.990,95% CI 1.640-38.100）. Conclusions 25（OH）D levels are correlated with thyroid cancer,and low 25（OH）D level may increase the risk of thyroid cancer.

Key words: 25-Hydroxyvitamin D, Thyroid function indicator, Thyroid cancer, Risk assessment

CLC Number:

R446.1

CHEN Gang, WANG Jing, DENG Qiang, CHEN Xi, HU Dong, ZHUANG Lidong. Correlation and risk assessment of serum 25（OH）D level and multiple thyroid function indicators in patients with thyroid cancer before operation[J]. Laboratory Medicine, 2020, 35(9): 885-888.

Figures/Tables 4

References 13

[1]	HEDAYATI M,ZARIF YEGANEH M,SHEIKHOLESLAMI S,et al.Diversity of mutations in the RET proto-oncogene and its oncogenic mechanism in medullary thyroid cancer[J]. Crit Rev Clin Lab Sci,2016,53(4):217-227.
[2]	董媛媛,张文学. 维生素D与疾病的关系概述[J]. 生物学教学,2018,43(7):2-4.
[3]	DANILOVIC D D L,FERRAZ-DE-SOUZA B,FABRI A W,et al. 25-Hydroxyvitamin D and TSH as risk factors or prognostic markers in thyroid carcinoma[J]. PLoS One,2016,11(10):e0164550.
[4]	ZHAO J,WANG H,ZHANG Z,et al.Vitamin D deficiency as a risk factor for thyroid cancer:a meta-analysis of case-control studies[J]. Nutrition,2019,57:5-11.
[5]	巫志宇,陈鸣. 维生素D的实验室检测及推广应用之思辨[J]. 中华检验医学杂志,2017,40(11):844-847.
[6]	中国抗癌协会甲状腺癌专业委员会(CATO). 甲状腺癌血清标志物临床应用专家共识(2017版)[J]. 中国肿瘤临床,2018,45(1):7-13.
[7]	曾琴,袁晶晶,谢忠建. 维生素D与甲状腺癌的研究现状[J]. 中华内分泌代谢杂志,2017,33(6):525-528.
[8]	向腾霄. 甲状腺结节/甲状腺癌患者血清维生素D水平的检测及意义[D]. 遵义:遵义医学院,2017.
[9]	CLINCKSPOOR I,VERLINDEN L,OVERBERGH L,et al.1,25-Dihydroxyvitamin D3 and a superagonistic analog in combination with paclitaxel or suberoylanilide hydroxamic acid have potent antiproliferative effects on anaplastic thyroid cancer[J]. J Steroid Biochem Mol Biol,2011,124(1-2):1-9.
[10]	AHN H Y,CHUNG Y J,PARK K Y,et al.Serum 25-hydroxyvitamin D level does not affect the aggressiveness and prognosis of papillary thyroid cancer[J]. Thyroid,2016,26(3):429-433.
[11]	朱旭东. 桥本氏甲状腺炎患者血清TPOAb、TgAb水平与病情的相关性分析[J]. 检验医学,2018,33(10):903-906.
[12]	MANSOURNIA N,MANSOURNIA M A,SAEEDI S,et al.The association between serum 25OHD levels and hypothyroid Hashimoto's thyroiditis[J]. J Endocrinol Invest,2014,37(5):473-476.
[13]	张维,安民民. AITD患者血清25(OH)D水平与甲状腺激素和自身抗体的相关性[J]. 浙江临床医学,2015,17(7):1067-1068.

组别	例数	25（OH）D₂/ （ng/mL）	25（OH）D₃/ （ng/mL）	25（OH）D/ （ng/mL）		FT₃/（pg/mL）		FT₄/（ng/L）
甲状腺癌组	56	1.36±0.54	16.82±6.32	18.65±5.32		3.21（2.58~3.65）		10.30（9.30~11.00）
良性结节组	69	4.55±1.14	21.74±8.53	26.32±7.41		3.08（2.48~3.41）		10.50（9.80~11.50）
统计值		-4.034	-3.109	-4.852		1.128		-0.776
P值		<0.01	<0.01	<0.01		0.429		0.444
组别	TSH/（mIU/mL）		Tg/（ng/L）		TPOAb/（IU/mL）		TgAb/（IU/mL）
甲状腺癌组	3.98（2.18~4.69）		10.48（3.15~189.23）		17.65（1.31.~56.23）		24.11（1.25~68.32）
良性结节组	2.27（1.61~3.78）		8.38（2.42~135.66）		14.28（0.89~73.65）		28.75（1.03~63.9）
统计值	2.831		1.041		0.837		-0.537
P值	0.018		0.351		0.599		0.586

组别	例数	25（OH）D₂/ （ng/mL）	25（OH）D₃/ （ng/mL）	25（OH）D/ （ng/mL）		FT₃/（pg/mL）		FT₄/（ng/L）
甲状腺癌组	56	1.36±0.54	16.82±6.32	18.65±5.32		3.21（2.58~3.65）		10.30（9.30~11.00）
良性结节组	69	4.55±1.14	21.74±8.53	26.32±7.41		3.08（2.48~3.41）		10.50（9.80~11.50）
统计值		-4.034	-3.109	-4.852		1.128		-0.776
P值		<0.01	<0.01	<0.01		0.429		0.444
组别	TSH/（mIU/mL）		Tg/（ng/L）		TPOAb/（IU/mL）		TgAb/（IU/mL）
甲状腺癌组	3.98（2.18~4.69）		10.48（3.15~189.23）		17.65（1.31.~56.23）		24.11（1.25~68.32）
良性结节组	2.27（1.61~3.78）		8.38（2.42~135.66）		14.28（0.89~73.65）		28.75（1.03~63.9）
统计值	2.831		1.041		0.837		-0.537
P值	0.018		0.351		0.599		0.586

组别	25（OH）D/（ng/mL）			合计
组别	≤20	>20~≤30	>30	合计
甲状腺癌组	46	8	2	56
良性结节组	32	26	11	69
χ²值	8.495	0.372		4.182
P值	0.004	0.542		0.041

组别	25（OH）D/（ng/mL）			合计
组别	≤20	>20~≤30	>30	合计
甲状腺癌组	46	8	2	56
良性结节组	32	26	11	69
χ²值	8.495	0.372		4.182
P值	0.004	0.542		0.041

[1]	PAN Xin, LÜ Ying, LI Yang, LI Rongguo. Effects of miR-24-3p targeting CHD5 on migration，invasion and radiosensitivity of thyroid cancer cells [J]. Laboratory Medicine, 2023, 38(7): 640-646.
[2]	LIU Qinqing, XU Jing, LIU Hua, LIU Yiwen, HE Yiqing, DU Yan, ZHANG Guoliang, GAO Feng, YANG Cuixia. Role of hyaluronan in thyroid nodule fine-needle aspiration washout fluid in differential diagnosis of papillary thyroid cancer [J]. Laboratory Medicine, 2023, 38(4): 320-324.
[3]	LIU Yang, GENG Kunjing, LI Hongjiang, SHI Haoxi, CHEN Sisi. Relationship of 25（OH）D₃ and liver inflammatory stage with the efficacy of antiviral therapy [J]. Laboratory Medicine, 2022, 37(7): 628-631.
[4]	ZHANG Zhibin, YANG Wanyong, RUAN Fuwang, WEN Qinghui. Roles of total IgE,sIgE and 25（OH）D in the evaluation of infant atopic dermatitis [J]. Laboratory Medicine, 2022, 37(3): 217-220.
[5]	ZHAO Xiaomin, JIANG Xiaoyu, SHAN Kaili, SHAN Tieying, LIU Xiuzhen. Roles of Flt-3L，TF and 25（OH）D in iron deficiency anemia among infants and children [J]. Laboratory Medicine, 2022, 37(11): 1039-1043.
[6]	ZHENG Yu, CHEN Jin. Correlation between serum follistatin and clinicopathological characteristics and prognosis of patients with differentiated thyroid cancer [J]. Laboratory Medicine, 2022, 37(11): 1066-1070.
[7]	LI Dingfu, HUANG Jian, CAI Meiling, WANG Lizhen, JIAN Kaigan, YANG Feifei. Relationship between serum 25（OH）D and disease control in children with allergic rhinitis-asthma syndrome [J]. Laboratory Medicine, 2022, 37(1): 32-35.
[8]	ZHAO Xueling, ZHENG Xin, XU Huamei, SHI Hongyao. Correlation between serum 25（OH）D,specific IgE and VAS score in children with allergic rhinitis [J]. Laboratory Medicine, 2021, 36(6): 615-617.
[9]	LI Bingling, CHENG Yating, ZHAO Beibei, SHE Xuhui, DONG Heng, YU Mujun. Evaluation of surrogate matrices for serum 25-hydroxyvitamin D calibrators by LC-MS/MS [J]. Laboratory Medicine, 2021, 36(2): 213-218.
[10]	FANG Huiling, GE Danhong, ZHU Yuqing, ZHU Lingfeng, ZHAO Xiaojun, CHEN Ziqi, WANG Zimeng. Analysis on the external quality assessment results for 25-hydroxyvitamin D of Shanghai from 2015 to 2019 [J]. Laboratory Medicine, 2021, 36(2): 219-224.
[11]	ZHANG Sujie, JU Yi, LI Qing, SUN Hewei, FENG Xueqing, JIN Zhonggan, LI Shuijun, LI Yujie, LI Jinrong. Analysis of serum 25-hydroxyvitamin D levels in healthy subjects [J]. Laboratory Medicine, 2020, 35(10): 1028-1031.
[12]	SUN Liangbo, JING Haining. Correlation of bioavailable 1,25（OD）₂D level with bone mineral density and bone metabolic markers in patients with nephrotic syndrome [J]. Laboratory Medicine, 2019, 34(8): 717-721.
[13]	LIANG Chunzi, ZHU Man, TU Jiancheng. Research progress of VAP in determining plasma lipoprotein subfractions [J]. Laboratory Medicine, 2019, 34(1): 76-81.
[14]	LIN Xiangquan, CHEN Hong. Roles of serum 25-hydroxyvitamin D and bone mineral density in children with obesity [J]. Laboratory Medicine, 2018, 33(8): 669-673.
[15]	LUO Qingxin, CHEN Kaiting, LAN Yanling, MO Xin, CHEN Jiaqiang. Additive effect of serum 25-hydroxyvitamin D₃ in the treatment of depression [J]. Laboratory Medicine, 2018, 33(6): 491-494.